110 related articles for article (PubMed ID: 17077548)
21. Pyrrolidinones as orally bioavailable antagonists of the human melanocortin-4 receptor with anti-cachectic activity.
Tran JA; Tucci FC; Jiang W; Marinkovic D; Chen CW; Arellano M; Markison S; Fleck BA; Wen J; White NS; Pontillo J; Saunders J; Marks D; Hoare SR; Madan A; Foster AC; Chen C
Bioorg Med Chem; 2007 Aug; 15(15):5166-76. PubMed ID: 17544282
[TBL] [Abstract][Full Text] [Related]
22. The orally active glutamate carboxypeptidase II inhibitor E2072 exhibits sustained nerve exposure and attenuates peripheral neuropathy.
Wozniak KM; Wu Y; Vornov JJ; Lapidus R; Rais R; Rojas C; Tsukamoto T; Slusher BS
J Pharmacol Exp Ther; 2012 Dec; 343(3):746-54. PubMed ID: 22988061
[TBL] [Abstract][Full Text] [Related]
23. Substituted N-(3,5-dichlorobenzenesulfonyl)-L-prolyl-phenylalanine analogues as potent VLA-4 antagonists.
Kopka IE; Young DN; Lin LS; Mumford RA; Magriotis PA; MacCoss M; Mills SG; Van Riper G; McCauley E; Egger LE; Kidambi U; Schmidt JA; Lyons K; Stearns R; Vincent S; Colletti A; Wang Z; Tong S; Wang J; Zheng S; Owens K; Levorse D; Hagmann WK
Bioorg Med Chem Lett; 2002 Feb; 12(4):637-40. PubMed ID: 11844689
[TBL] [Abstract][Full Text] [Related]
24. Identification of N-acyl 4-(3-pyridonyl)phenylalanine derivatives and their orally active prodrug esters as dual acting α4β1 and α4β7 receptor antagonists.
Tilley JW; Sidduri A; Lou J; Kaplan G; Tare N; Cavallo G; Frank K; Pamidimukkala A; Choi DS; Gerber L; Railkar A; Renzetti L
Bioorg Med Chem Lett; 2013 Feb; 23(4):1036-40. PubMed ID: 23312471
[TBL] [Abstract][Full Text] [Related]
25. Bioisosteric replacement of anilide with benzoxazole: potent and orally bioavailable antagonists of VLA-4.
Lin LS; Lanza TJ; Castonguay LA; Kamenecka T; McCauley E; Van Riper G; Egger LA; Mumford RA; Tong X; MacCoss M; Schmidt JA; Hagmann WK
Bioorg Med Chem Lett; 2004 May; 14(9):2331-4. PubMed ID: 15081035
[TBL] [Abstract][Full Text] [Related]
26. N-aryl-prolyl-dipeptides as potent antagonists of VLA-4.
Kamenecka TM; Lanza T; de Laszlo SE; Li B; McCauley ED; Van Riper G; Egger LA; Kidambi U; Mumford RA; Tong S; MacCoss M; Schmidt JA; Hagmann WK
Bioorg Med Chem Lett; 2002 Aug; 12(16):2205-8. PubMed ID: 12127538
[TBL] [Abstract][Full Text] [Related]
27. Rational design of potent and selective VLA-4 inhibitors and their utility in the treatment of asthma.
Singh J; Adams S; Carter MB; Cuervo H; Lee WC; Lobb RR; Pepinsky RB; Petter R; Scott D
Curr Top Med Chem; 2004; 4(14):1497-507. PubMed ID: 15544540
[TBL] [Abstract][Full Text] [Related]
28. Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: a highly potent orally available CCR5 selective antagonist.
Nishizawa R; Nishiyama T; Hisaichi K; Minamoto C; Murota M; Takaoka Y; Nakai H; Tada H; Sagawa K; Shibayama S; Fukushima D; Maeda K; Mitsuya H
Bioorg Med Chem; 2011 Jul; 19(13):4028-42. PubMed ID: 21658961
[TBL] [Abstract][Full Text] [Related]
29. Imidazopyridines as VLA-4 integrin antagonists.
Phillips DJ; Davenport RJ; Demaude TA; Galleway FP; Jones MW; Knerr L; Perry BG; Ratcliffe AJ
Bioorg Med Chem Lett; 2008 Jul; 18(14):4146-9. PubMed ID: 18539454
[TBL] [Abstract][Full Text] [Related]
30. The discovery of VLA-4 antagonists.
Tilley JW; Chen L; Sidduri A; Fotouhi N
Curr Top Med Chem; 2004; 4(14):1509-23. PubMed ID: 15544541
[TBL] [Abstract][Full Text] [Related]
31. Discovery of N-{N-[(3-cyanophenyl)sulfonyl]-4(R)-cyclobutylamino-(L)-prolyl}-4-[(3',5'-dichloroisonicotinoyl) amino]-(L)-phenylalanine (MK-0668), an extremely potent and orally active antagonist of very late antigen-4.
Lin LS; Lanza T; Jewell JP; Liu P; Jones C; Kieczykowski GR; Treonze K; Si Q; Manior S; Koo G; Tong X; Wang J; Schuelke A; Pivnichny J; Wang R; Raab C; Vincent S; Davies P; Maccoss M; Mumford RA; Hagmann WK
J Med Chem; 2009 Jun; 52(11):3449-52. PubMed ID: 19441819
[TBL] [Abstract][Full Text] [Related]
32. Discovery of N-{N-[(3-cyanobenzene) sulfonyl]-4(R)-(3,3-difluoropiperidin-1-yl)-(l)-prolyl}-4-[(3',5'-dichloro-isonicotinoyl) amino]-(l)-phenylalanine (MK-0617), a highly potent and orally active VLA-4 antagonist.
Venkatraman S; Lebsack AD; Alves K; Gardner MF; James J; Lingham RB; Maniar S; Mumford RA; Si Q; Stock N; Treonze KM; Wang B; Zunic J; Munoz B
Bioorg Med Chem Lett; 2009 Oct; 19(19):5803-6. PubMed ID: 19713111
[TBL] [Abstract][Full Text] [Related]
33. 2,3-Diphenylpropionic acids as potent VLA-4 antagonists.
Hoshina Y; Ikegami S; Okuyama A; Fukui H; Inoguchi K; Maruyama T; Fujimoto K; Matsumura Y; Aoyama A; Harada T; Tanaka H; Nakamura T
Bioorg Med Chem Lett; 2005 Jan; 15(1):217-20. PubMed ID: 15582442
[TBL] [Abstract][Full Text] [Related]
34. Dehydrophenylalanine derivatives as VLA-4 integrin antagonists.
Porter JR; Archibald SC; Brown JA; Childs K; Critchley D; Head JC; Parton TA; Robinson MK; Shock A; Taylor RJ; Warrellow GJ
Bioorg Med Chem Lett; 2003 Mar; 13(5):805-8. PubMed ID: 12617895
[TBL] [Abstract][Full Text] [Related]
35. Synthetic study of VLA-4/VCAM-1 inhibitors: synthesis and structure-activity relationship of piperazinylphenylalanine derivatives.
Saku O; Ohta K; Arai E; Nomoto Y; Miura H; Nakamura H; Fuse E; Nakasato Y
Bioorg Med Chem Lett; 2008 Feb; 18(3):1053-7. PubMed ID: 18160288
[TBL] [Abstract][Full Text] [Related]
36. Investigation of the teratogenic potential of VLA-4 antagonist derivatives in rats.
Sakurai K; Matsuoka T; Suzuki C; Kinoshita J; Takayama G; Shimomura K
Reprod Toxicol; 2014 Nov; 49():162-70. PubMed ID: 25194688
[TBL] [Abstract][Full Text] [Related]
37. Synthesis, characterization and evaluation of pro-drugs of VLA-4 antagonists.
Huryn DM; Ashwell S; Baudy R; Dressen DB; Gallaway W; Grant FS; Konradi A; Ley RW; Petusky S; Pleiss MA; Sarantakis D; Semko CM; Sherman MM; Tio C; Zhang L
Bioorg Med Chem Lett; 2004 Apr; 14(7):1651-4. PubMed ID: 15026043
[TBL] [Abstract][Full Text] [Related]
38. Pyridone derivatives as potent and selective VLA-4 integrin antagonists.
Witherington J; Bordas V; Gaiba A; Green PM; Naylor A; Parr N; Smith DG; Takle AK; Ward RW
Bioorg Med Chem Lett; 2006 Apr; 16(8):2256-9. PubMed ID: 16455247
[TBL] [Abstract][Full Text] [Related]
39. Influence of acid surrogates toward potency of VLA-4 antagonist.
Venkatraman S; Lim J; Cramer M; Gardner MF; James J; Alves K; Lingham RB; Mumford RA; Munoz B
Bioorg Med Chem Lett; 2005 Sep; 15(18):4053-6. PubMed ID: 16039122
[TBL] [Abstract][Full Text] [Related]
40. N-(arylacetyl)-biphenylalanines as potent VLA-4 antagonists.
Li B; de Laszlo SE; Kamenecka TM; Kopka IE; Durette PL; Lanza T; MacCoss M; Tong S; Mumford RA; McCauley ED; Van Riper G; Schmidt JA; Hagmann WK
Bioorg Med Chem Lett; 2002 Aug; 12(16):2141-4. PubMed ID: 12127523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
